Mdd Us Drug Patent Portfolio
Mdd Us owns 1 orange book drug protected by 3 US patents Given below is the list of Mdd Us's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8283380 | Methods for treatment of parkinson's disease | 21 Mar, 2031 | Active |
| US8076515 | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides | 10 Dec, 2028 | Active |
| US8278485 | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides | 08 Jun, 2027 | Active |
Latest Legal Activities on Mdd Us's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mdd Us.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Apr, 2024 | US8283380 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Apr, 2024 | US8278485 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jun, 2023 | US8076515 |
|
Patent Term Extension Certificate
Critical
| 21 May, 2021 | US8283380 |
|
Withdrawal of Application for PTE
Critical
| 20 May, 2021 | US8076515 |
| Election in Response to Notice of Final Determination | 16 Mar, 2021 | US8283380 |
| Notice of Final Determination -Election Required | 09 Mar, 2021 | US8283380 |
| Notice of Final Determination -Election Required | 09 Mar, 2021 | US8076515 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Apr, 2020 | US8283380 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Apr, 2020 | US8278485 |
|
FDA Final Eligibility Letter
Critical
| 16 Sep, 2019 | US8283380 |
|
FDA Final Eligibility Letter
Critical
| 16 Sep, 2019 | US8076515 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jun, 2019 | US8076515 |
| transaction for FDA Determination of Regulatory Review Period | 12 Feb, 2019 | US8076515 |
| transaction for FDA Determination of Regulatory Review Period | 11 Feb, 2019 | US8283380 |
Mdd Us's Family Patents
Mdd Us drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 6.7% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Mdd Us Drug List
Given below is the complete list of Mdd Us's drugs and the patents protecting them.
1. Xadago
Xadago is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8283380 | Methods for treatment of parkinson's disease |
21 Mar, 2031
(6 years from now)
| Active |
| US8076515 | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
10 Dec, 2028
(3 years from now)
| Active |
| US8278485 | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
08 Jun, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xadago's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List